NAVIDEA BIOPHARMACEUTICALS, INC.

Form 4

December 12, 2014

FORM	$14_{\text{UNITED S}}$	UNITED STATES SECURITIES AND EXCHANGE COMMISSION						OMB APPROVAL		
Check the		Washington, D.C. 20549								
if no long subject to Section 1 Form 4 o Form 5 obligation may cont See Instru 1(b).	ger STATEM 6. r Filed purs ns Section 17(a)	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section						January 31, 2005 average rs per 0.5		
(Print or Type I	Responses)									
LARSON BRENT L Syn			er Name and Tic DEA IARMACEUT B]	·		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last)	(First) (M		5. Date of Earliest Transaction belo			_X_ Officer (give below)	below)			
(Month/Day/Year) EVP, CFO, Treas and Secy 12/10/2014								ecy		
			endment, Date Original nth/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
DUBLIN, C	OH US 43017					Form filed by M Person	Iore than One Re	porting		
(City)	(State) (Z	Zip) Tab	ole I - Non-Deriv	vative Securit	ties Acq	uired, Disposed of	, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	n Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) Day/Year) (Instr. 8) (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)				
Common	12/10/2014			amount (D) 0,000 A	Price \$	369,184	D			
Stock	_, _ , _ , _ ,				0.39	,				
Common Stock	12/10/2014		F (1)	6,947 D	\$ 1.31	342,237	D			
Common Stock						95,097	I	By 401(k)		

Persons who respond to the collection of

information contained in this form are not

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1474

(9-02)

Edgar Filing: NAVIDEA BIOPHARMACEUTICALS, INC. - Form 4

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 0.39	12/10/2014		M	50,000	(2)	12/10/2014	Common Stock	50,000	

Reporting Owners

Reporting Owner Name / Address	Relationships					
. 0	Director	10% Owner	Officer	Other		
LARSON BRENT L 5600 BLAZER PARKWAY, SUITE 200 DUBLIN, OH US 43017			EVP, CFO, Treas and Secv			

Signatures

William J. Kelly, Attorney-in-Fact

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares withheld by the issuer in payment of the option exercise price and to satisfy tax withholding obligations.
- (2) Option vested 1/3 of the underlying shares annually beginning on 12/10/2005.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2